All Articles

Hevolution Foundation Is Backing A New Longevity Startup

April 1, 2024
x min read

The race to build a biotechnology company capable of extending human lifespan is underway.

What’s happening:

  • Hevolution Foundation has announced they have led a $50 million Series A financing round for longevity biotechnology company Aeovian Pharmaceuticals
  • The round also saw notable participation from Apollo Health Ventures, Sofinnova Investments, Evotec and others

The big idea:

  • Aeovian is developing novel therapeutic compounds that target highly selective small molecules to restore cellular metabolic quality
  • The therapeutics compounds being developed by Aeovian are aiming to combat the dysregulated growth and hyperactive signalling that is commonly found in rare genetic disease and age related diseases

Why it matters:

Going deeper:

  • Aeovian Pharmaceuticals has also recently begun dosing patients in their first ever Phase I clinical trial for the treatment of seizures and Tuberous Sclerosis Complex

The intrigue:

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.